Results 131 to 140 of about 592,196 (366)

TRIM40 Drives Pathological Cardiac Hypertrophy and Heart Failure via Ubiquitination of PKN2

open access: yesAdvanced Science, EarlyView.
This study identifies the E3 ligase TRIM40 as a key driver of pathological cardiac hypertrophy. TRIM40 binds PKN2 via its B‐box domain and, through its C29‐dependent catalytic activity, mediates K63‐linked ubiquitination of PKN2. This modification enhances PKN2 phosphorylation at Ser815, thereby driving hypertrophy.
Risheng Zhao   +12 more
wiley   +1 more source

Malignant Peritoneal Mesothelioma: Clinicopathological Characteristics of Two Cases

open access: yesCase Reports in Surgery, 2014
Introduction. Peritoneal mesothelioma is a rare tumor, presenting difficulties in diagnosis and treatment. Peritoneum is the second most common area of the mesothelioma after pleura, and even synchronous pleural and peritoneal mesotheliomas are observed ...
Mustafa Cem Algın   +4 more
doaj   +1 more source

P.L.E.A.T.-Preventing Lymphocele Ensuring Absorption Transperitoneally: A Robotic Technique [PDF]

open access: yes, 2017
OBJECTIVE: To reduce the risk of symptomatic lymphocele after robotic pelvic lymph node dissection (PLND), we present a novel technique, preventing lymphocele ensuring absorption transperitoneally (P.L.E.A.T.), where the peritoneum is "pleated" along its
DAL MORO, Fabrizio, Zattoni, Filiberto
core   +1 more source

Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity

open access: yesAdvanced Science, EarlyView.
TM4SF1‐nanobody engineered CAR‐natural killer T–derived extracellular vesicles (CARTM4SF1‐EVs) provide a cell‐free alternative to CAR‐NKT therapy, achieving potent, targeted antitumor activity with reduced toxicity. CARTM4SF1‐EVs induce immunogenic cell death, remodel the tumor microenvironment, and enhance CD8⁺ T‐cell antitumor immunity.
Xiaopei Hao   +14 more
wiley   +1 more source

Case Report: Insights into multiple cases of Pseudomyxoma peritonei

open access: yesFrontiers in Gastroenterology
As a rare peritoneal malignant tumor, Pseudomyxoma peritonei (PMP) is a challenge in the field of surgery and oncology due to its complex pathological mechanism and difficult clinical management.
HanJie Chu, XiaoBiao Song
doaj   +1 more source

Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab [PDF]

open access: yes, 2015
Published online: May 7, 2015Aim: To investigate the safety and efficacy of adding bevacizumab to first-line chemotherapy in metastatic colorectal cancer patients with peritoneal disease.
Chantrill, L.   +15 more
core   +2 more sources

Systematic Review and Meta‐Analysis of Short‐ and Long‐Term Outcomes Following Natural Orifice Specimen Extraction for Colon Cancer

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Natural orifice specimen extraction (NOSE) in colon cancer surgery raises concerns about intra‐abdominal infection, peritoneal seeding, and local recurrence due to possible tumor cell implantation. This systematic review and meta‐analysis compares complete intracorporeal resection with NOSE versus conventional laparoscopic colon ...
Daichi Kitaguchi   +4 more
wiley   +1 more source

Delayed phlegmon with gallstone fragments masquerading as soft tissue sarcoma. [PDF]

open access: yes, 2016
Complications from lost gallstones after cholecystectomy are rare but varied from simple perihepatic abscess to empyema and expectoration of gallstones.
Bateni, Cyrus P   +3 more
core   +1 more source

Impact of Combined Resection of the Pancreas on Long‐Term Survival in Gastric Cancer

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
Short‐term and long‐term results of patients underwent conbined pancreatectomy was investigated in 64 patients with gastric cancer. R1 resection and postoperative intraabdominal infectious complications were identified as independent prognostic factors.
Taku Hattori   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy